Your browser doesn't support javascript.
Population-level interest in anti-rheumatic drugs in the COVID-19 era: insights from Google Trends.
Kardes, Sinan; Kuzu, Ali Suat; Pakhchanian, Haig; Raiker, Rahul; Karagülle, Mine.
  • Kardes S; Department of Medical Ecology and Hydroclimatology, Istanbul Faculty of Medicine, Istanbul University, Capa-Fatih, 34093, Istanbul, Turkey. sinan.kardes@istanbul.edu.tr.
  • Kuzu AS; Department of Medical Ecology and Hydroclimatology, Istanbul Faculty of Medicine, Istanbul University, Capa-Fatih, 34093, Istanbul, Turkey.
  • Pakhchanian H; George Washington University School of Medicine & Health Science, Washington, DC, USA.
  • Raiker R; West Virginia University School of Medicine, Morgantown, WV, USA.
  • Karagülle M; Department of Medical Ecology and Hydroclimatology, Istanbul Faculty of Medicine, Istanbul University, Capa-Fatih, 34093, Istanbul, Turkey.
Clin Rheumatol ; 40(5): 2047-2055, 2021 May.
Article in English | MEDLINE | ID: covidwho-898035
ABSTRACT
INTRODUCTION/

OBJECTIVE:

The general public may utilize online information through search engines for implications and risks of some anti-rheumatic drugs. These drugs have been used in the management of coronavirus disease 2019 (COVID-19) and associated inflammatory sequelae or cytokine storm of infection. Therefore, the objective of this study was to investigate the population-level interest in anti-rheumatic drugs during the COVID-19 era, by analyzing changes in Google search frequency data.

METHOD:

To obtain the relative search volume (RSV) of anti-rheumatic drugs, we queried Google Trends for 78 search terms representing non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, antigout agents, conventional disease-modifying anti-rheumatic drugs (DMARDs), immunosuppressants, biologics, and Janus kinase (JAK) inhibitors within the USA. Three 8-week periods in 2020 (March 15-May 9), (May 10-July 4), and (July 5-August 29) representing the initial- and short-term periods were compared to overlapping periods of the preceding 3 years (2017-2019).

RESULTS:

We found statistically significant increases in RSV for colchicine, hydroxychloroquine, tocilizumab (and its brand name-Actemra), and anakinra, and statistically significant decreases among brand names of immunosuppressive agents (i.e., mycophenolate mofetil, azathioprine, cyclophosphamide, tacrolimus, cyclosporine) during both the initial- and short-term COVID-19 periods as compared to overlapping periods of the preceding 3 years.

CONCLUSION:

There were significant increases in RSV of colchicine, hydroxychloroquine, tocilizumab, and anakinra during both initial- and short-term COVID-19 periods when compared to overlapping periods of the preceding 3 years reflecting a heightened level of information-seeking on these drugs during the pandemic. Rheumatologists should address this increase in informational demand. Further research assessing medium- and long-term interest in anti-rheumatic drugs is required to increase our knowledge on this new pandemic. Key Points •This study was aimed to investigate the population-level interest in anti-rheumatic drugs in the COVID-19 era, by analyzing changes in Google search frequency data. •Significant increases were seen in relative searches for colchicine, hydroxychloroquine, tocilizumab, and anakinra during both initial and short-term COVID-19 periods when compared to similar periods of 2017-2019 reflecting a heightened level of information-seeking on these drugs during the pandemic. •Rheumatologists should address this increase in informational demand for colchicine, hydroxychloroquine, tocilizumab, and anakinra.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antirheumatic Agents / COVID-19 Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Clin Rheumatol Year: 2021 Document Type: Article Affiliation country: S10067-020-05490-w

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antirheumatic Agents / COVID-19 Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Clin Rheumatol Year: 2021 Document Type: Article Affiliation country: S10067-020-05490-w